On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for the label to ...

Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

(RTTNews) - Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling certain Insulin Glargine (Insulin glargine-yfgn) Injection prefilled pens due to the potential for ...

PORTLAND, Ore. (KOIN) — A recall has been issued for insulin pens from one manufacturer because they may not have labels on the injectors, the Food and Drug Administration said in a press release ...

Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons of five. Some pens might be missing their labels. In ...

Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection pens due to the potential for missing labels, according to a press release from the FDA.

Lantus (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for diabetes. It’s used in adults and some children. The cost of the drug with and without insurance can depend on ...

On November 18th, the U.S. Food and Drug Administration (FDA) announced its approval of Eli Lilly's Rezvoglar (insulin glargine-aglr) product as an interchangeable biosimilar to Sanofi's Lantus ...

TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device ...